Literature DB >> 30328784

Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development.

Peter Karagiannis1, Kazutoshi Takahashi1, Megumu Saito1, Yoshinori Yoshida1, Keisuke Okita1, Akira Watanabe1, Haruhisa Inoue1, Jun K Yamashita1, Masaya Todani1, Masato Nakagawa1, Mitsujiro Osawa1, Yoshimi Yashiro1, Shinya Yamanaka1, Kenji Osafune1.   

Abstract

The discovery of somatic cell nuclear transfer proved that somatic cells can carry the same genetic code as the zygote, and that activating parts of this code are sufficient to reprogram the cell to an early developmental state. The discovery of induced pluripotent stem cells (iPSCs) nearly half a century later provided a molecular mechanism for the reprogramming. The initial creation of iPSCs was accomplished by the ectopic expression of four specific genes (OCT4, KLF4, SOX2, and c-Myc; OSKM). iPSCs have since been acquired from a wide range of cell types and a wide range of species, suggesting a universal molecular mechanism. Furthermore, cells have been reprogrammed to iPSCs using a myriad of methods, although OSKM remains the gold standard. The sources for iPSCs are abundant compared with those for other pluripotent stem cells; thus the use of iPSCs to model the development of tissues, organs, and other systems of the body is increasing. iPSCs also, through the reprogramming of patient samples, are being used to model diseases. Moreover, in the 10 years since the first report, human iPSCs are already the basis for new cell therapies and drug discovery that have reached clinical application. In this review, we examine the generation of iPSCs and their application to disease and development.

Entities:  

Mesh:

Year:  2019        PMID: 30328784     DOI: 10.1152/physrev.00039.2017

Source DB:  PubMed          Journal:  Physiol Rev        ISSN: 0031-9333            Impact factor:   37.312


  63 in total

Review 1.  State of the field: cellular and exosomal therapeutic approaches in vascular regeneration.

Authors:  Evan Paul Tracy; Virginia Stielberg; Gabrielle Rowe; Daniel Benson; Sara S Nunes; James B Hoying; Walter Lee Murfee; Amanda Jo LeBlanc
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-02-18       Impact factor: 4.733

2.  Identification of microRNAs related with neural germ layer lineage-specific progenitors during reprogramming.

Authors:  Ruizhen Sun; Tiantian Gong; Hui Liu; Jingling Shen; Bin Wu; Qi Jiang; Qi Wang; Yue Zhang; Lian Duan; Jing Hu; Qiuming Li; Lei Lei; Zhiyan Shan
Journal:  J Mol Histol       Date:  2022-07-23       Impact factor: 3.156

3.  Generation and optimization of highly pure motor neurons from human induced pluripotent stem cells via lentiviral delivery of transcription factors.

Authors:  Masood Sepehrimanesh; Baojin Ding
Journal:  Am J Physiol Cell Physiol       Date:  2020-08-12       Impact factor: 4.249

4.  Gene-edited human stem cell-derived β cells from a patient with monogenic diabetes reverse preexisting diabetes in mice.

Authors:  Kristina G Maxwell; Punn Augsornworawat; Leonardo Velazco-Cruz; Michelle H Kim; Rie Asada; Nathaniel J Hogrebe; Shuntaro Morikawa; Fumihiko Urano; Jeffrey R Millman
Journal:  Sci Transl Med       Date:  2020-04-22       Impact factor: 17.956

5.  Genetically edited CD34+ cells derived from human iPS cells in vivo but not in vitro engraft and differentiate into HIV-resistant cells.

Authors:  Maelig G Morvan; Fernando Teque; Lin Ye; Mary E Moreno; Jiaming Wang; Scott VandenBerg; Cheryl A Stoddart; Yuet Wai Kan; Jay A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-18       Impact factor: 11.205

Review 6.  Modeling Type 1 Diabetes Using Pluripotent Stem Cell Technology.

Authors:  Kriti Joshi; Fergus Cameron; Swasti Tiwari; Stuart I Mannering; Andrew G Elefanty; Edouard G Stanley
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-01       Impact factor: 5.555

Review 7.  Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges.

Authors:  Fei Lu; Xiao-Jing-Nan Ma; Wei-Lin Jin; Yang Luo; Xun Li
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

Review 8.  iPSC technology-based regenerative medicine for kidney diseases.

Authors:  Kenji Osafune
Journal:  Clin Exp Nephrol       Date:  2021-03-03       Impact factor: 2.801

Review 9.  Stem Cell Models and Gene Targeting for Human Motor Neuron Diseases.

Authors:  Yashashree Karpe; Zhenyu Chen; Xue-Jun Li
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-12

Review 10.  Williams syndrome.

Authors:  Beth A Kozel; Boaz Barak; Chong Ae Kim; Carolyn B Mervis; Lucy R Osborne; Melanie Porter; Barbara R Pober
Journal:  Nat Rev Dis Primers       Date:  2021-06-17       Impact factor: 65.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.